Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Eicosanoids
A class of compounds named after and generally derived from C20 fatty acids (EICOSANOIC ACIDS) that includes PROSTAGLANDINS; LEUKOTRIENES; THROMBOXANES, and HYDROXYEICOSATETRAENOIC ACIDS. They have hormone-like effects mediated by specialized receptors (RECEPTORS, EICOSANOID).
Year introduced: 1990
Receptors, Eicosanoid
Cell surface proteins that bind eicosanoids with high affinity and trigger intracellular changes influencing the behavior of cells. Among the eicosanoid receptors are receptors for the prostaglandins, thromboxanes, and leukotrienes.
Year introduced: 1994
Oxylipins
Eighteen-carbon cyclopentyl polyunsaturated fatty acids derived from ALPHA-LINOLENIC ACID via an oxidative pathway analogous to the EICOSANOIDS in animals. Biosynthesis is inhibited by SALICYLATES. A key member, jasmonic acid of PLANTS, plays a similar role to ARACHIDONIC ACID in animals.
Year introduced: 2008
Fatty Acid-Binding Proteins
Intracellular proteins that reversibly bind hydrophobic ligands including: saturated and unsaturated FATTY ACIDS; EICOSANOIDS; and RETINOIDS. They are considered a highly conserved and ubiquitously expressed family of proteins that may play a role in the metabolism of LIPIDS.
Year introduced: 2006
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
Year introduced: 1992
CYP4F11 protein, human [Supplementary Concept]
CYP4F isoform involved in the metabolism of therapeutic drugs and eicosanoids; RefSeq NM_021187
Date introduced: October 28, 2004
15-hydroxyeicosatrienoic acid [Supplementary Concept]
the 15-lipoxygenase product of dihomogammalinolenic acid; inhibits the biosynthesis of the proinflammatory eicosanoids leukotriene B4 (LTB4) and 12-hydroxyeicosatetraenoic acid
Date introduced: September 14, 1995
15-hydroxyeicosatetraenoic acid dehydrogenase (NAD(P)) [Supplementary Concept]
from microsomal fraction of mouse liver homogenate; catalyzes the conversion of 15-HETE to 15-ketoeicosatetraenoic acid in the presence of NAD(P); utilizes other hydroxylated eicosanoids as substrates
Date introduced: November 15, 1988